Compound-centered research, organized for rigorous review.

BPC-157 is a chemically synthesized linear peptide composed of 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, commonly abbreviated as GEPPPGKPADDAGLV.

The name is often expanded as “Body Protection Compound 157,” and the peptide is frequently described as a “stable gastric pentadecapeptide.” Those phrases reflect its development history, but they require context. The Zagreb research group that originated the program described a larger bioactive material isolated from human gastric juice and proposed that the synthetic 15-residue sequence retained part of its activity.

CJC-1295 without DAC is a common name for a synthetic 29-amino-acid analogue of the active N-terminal portion of human growth hormone–releasing hormone (GHRH). The most precise description is [D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷]-hGRF(1-29)-NH₂. The same intended sequence is frequently called Modified GRF (1-29) or Mod GRF 1-29.

Those names are useful, but they carry an important historical complication. In the original ConjuChem development program, the name CJC-1295 referred to a longer, albumin-binding derivative that added a maleimide-bearing lysine to the 29-residue core. The added group—the Drug Affinity Complex, or DAC—was designed to form a covalent bond with circulating albumin and substantially extend exposure.

GHK-Cu is a copper-binding tripeptide coordination system studied across copper chemistry, extracellular-matrix biology, skin appearance, wound research, hair research, and safety or regulatory contexts.

The evidence record separates free GHK, GHK-Cu, prezatide copper acetate, AHK-Cu, ALAVAX, and proprietary copper-peptide formulations so findings remain tied to the tested identity and material.

Ipamorelin, development code NNC 26-0161, is a synthetic amidated pentapeptide developed within Novo Nordisk’s growth-hormone-secretagogue research program. Its sequence is Aib–His–D-2-Nal–D-Phe–Lys–NH₂, where Aib and D-2-Nal are non-proteinogenic amino-acid residues.

Unlike GHRH analogues such as tesamorelin or Modified GRF (1-29), ipamorelin acts through the ghrelin/growth-hormone-secretagogue receptor, GHS-R1a. Activation of this receptor can stimulate a transient release of endogenous growth hormone through hypothalamic and pituitary pathways.

LY3437943, the investigational molecule developed by Eli Lilly and commonly known as retatrutide, has become one of the most closely watched subjects in current metabolic research. It was designed to activate three hormone receptors studied in appetite, glucose, and energy-metabolism pathways: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). This three-receptor design is why the molecule is commonly called a “triple agonist.”

In randomized human trials of Lilly’s investigated molecule, researchers reported unusually large changes in body-weight endpoints and meaningful changes in prespecified glycemic measures. Emerging datasets also reported signals involving liver fat, sleep-apnea endpoints, body composition, and knee-osteoarthritis symptoms. Together, these findings have made the triple-receptor strategy an important research question within the incretin field.

The best-supported product-specific definition of TB-500 is an N-terminally acetylated seven-amino-acid peptide: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, abbreviated Ac-LKKTETQ. It corresponds to residues 17–23 within the much larger endogenous protein thymosin beta-4.

Full-length mature human thymosin beta-4—also called Tβ4 or timbetasin—is a 43-amino-acid peptide encoded by the TMSB4X gene. It contains the LKKTETQ sequence, but also includes substantial N-terminal and C-terminal regions absent from TB-500.

Tesamorelin is a synthetic analogue of the human growth hormone–releasing hormone sequence GHRH(1–44). A trans-3-hexenoic-acid modification at the N-terminus increases resistance to enzymatic degradation while preserving activity at the GHRH receptor.

That receptor-level design distinguishes tesamorelin from compounds that act directly at the growth hormone receptor. In the investigated clinical products, GHRH-receptor activation stimulated pituitary growth hormone release and increased downstream insulin-like growth factor 1 (IGF-1). The pathway retains more of the pituitary axis than direct administration of growth hormone, although increased GH–IGF-1 signaling remains central to both the observed endpoints and the safety questions.

Tirzepatide is one of the best-developed examples of a modern incretin-receptor research program. The molecule began as LY3298176 and is now the active pharmaceutical ingredient in two Eli Lilly finished drug products, Mounjaro and Zepbound.

That distinction matters: the research record is not evidence for every material that carries the name tirzepatide.